Modulating the activities of costimulatory molecules controlling immune responses holds considerable promise for immunotherapy. CTLA4Ig (abatacept), a soluble version of the T cell-expressed membrane receptor CTLA-4, is approved for the treatment of rheumatoid arthritis. Like natural CTLA-4 molecules, CTLA4Ig ligates B7-1 and B7-2 on antigen presenting cells, preventing CD28-mediated costimulation of T cells. However, CTLA4Ig can also prevent ligation of CTLA-4, potentially blocking vital inh...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Quantitative analysis predicts the relative therapeutic efficacy of different forms of CTLA4Ig.
If you are the owner of this record, you can report an update to it here: Report update to this record